Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline

다국어 초록 (Multilingual Abstract)

Prosthesis retention is not recommended for multidrug-resistant Acinetobacter prosthetic joint infection due to its high failure rate. Nevertheless, replacing the prosthesis implies high morbidity and prolonged hospitalization. Although tigecycline is not approved for the treatment of prosthetic joint infection due to multidrug resistant Acinetobacter baumannii, its appropriate use may preclude prosthesis exchange. Since the area under the curve divided by the minimum inhibitory concentration is the best pharmacodynamic predictor of its efficacy, we used tigecycline at high dose, in order to optimize its efficacy and achieve implant retention in 3 patients who refused prosthesis exchange. All patients with prosthetic joint infections treated at our Institution are prospectively registered in a database. Three patients with early prosthetic joint infection of total hip arthroplasty due to multidrug resistant A. baumannii were treated with debridement, antibiotics and implant retention, using a high maintenance dose of tigecycline (100 mg every 12 hours). The cases were retrospectively reviewed. All patients signed informed consent for receiving off-label use of tigecycline.
Tigecycline was well tolerated, allowing its administration at high maintenance dose for a median of 40 days (range 30–60). Two patients were then switched to minocycline at standard doses for a median of 3.3 months in order to complete treatment. Currently, none of the patients showed relapse. Increasing the dose of tigecycline could be considered as a means to better attain pharmacodynamic targets in patients with severe or difficult-to-treat infections. Tigecycline at high maintenance dose might be useful when retention of the implant is attempted for treatment for prosthetic joint infections due to multidrug resistant Acinetobacter. Although this approach might be promising, off-label use of tigecycline should be interpreted cautiously until prospective data are available. Tigecycline is probably under-dosed for the treatment of implant and biofilm associated infections.

참고문헌 (Reference)

1 Bengtsson S, "Validation of EUCAST zone diameter breakpoints against reference broth microdilution" 20 : O353-O360, 2014

2 Zhang Q, "Tigecycline treatment causes a decrease in fibrinogen levels" 59 : 1650-1655, 2015

3 MacGowan AP, "Tigecycline pharmacokinetic/pharmacodynamic update" 62 (62): i11-i16, 2008

4 Humphries RM, "Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin" 59 : 1383-1386, 2010

5 Rodvold KA, "Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose" 58 : 1221-1229, 2006

6 Ramirez J, "Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia" 57 : 1756-1762, 2013

7 Trampuz A, "Prosthetic joint infections: update in diagnosis and treatment" 135 : 243-251, 2005

8 Cunha BA, "Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis" 47 : 1613-, 2009

9 Xie J, "Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation" 18 : 62-67, 2014

10 Schafer JJ, "Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq" 14 : 512-514, 2008

11 Jones RN, "Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp" 45 : 227-230, 2007

12 Jaén N, "Long-term outcome of acute prosthetic joint infections due to gram-negative bacilli treated with retention of prosthesis" 25 : 194-198, 2012

13 De Pascale G, "High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria" 18 : R90-, 2014

14 Osmon DR, "Executive summary:diagnosis and management of prosthetic joint infection:clinical practice guidelines by the infectious diseases society of America" 56 : 1-10, 2013

15 Prasad P, "Excess deaths associated with tigecycline after approval based on noninferiority trials" 54 : 1699-1709, 2012

16 Beieler AM, "Eradication of multidrug-resistant Acinetobacter bau-mannii in a female patient with total hip arthroplasty, with debridement and retention: a case report" 3 : 45-, 2009

17 Falagas ME, "Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections" 44 : 1-7, 2014

18 Jones RN, "Disk diffusion susceptibility test development for the new glycylcycline, GAR-936" 35 : 249-252, 1999

19 Karani O, "Assessment of dosage regimens of tigecycline in hospitalised patients" 20 : 2165-, 2011

20 Estes CS, "A twostage retention debridement protocol for acute periprosthetic joint infections" 468 : 2029-2038, 2010